Acumen Pharmaceuticals, Inc. (ABOS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Newton, VA, United States. The current CEO is James Doherty.
ABOS has IPO date of 2021-07-01, 61 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $162.34M.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
